Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Telix Pharmaceuticals Ltd

TLX · Nasdaq; OTC · CIK 0002007191 · Healthcare · Biotechnology

INSIDER SIGNAL

59.6 / 100

2 buyers · 3 purchase transaction lines · $1.0M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeModerate
RoleModerate
RecencyModerate
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+17.6 / 25
Role+13.0 / 20
Recency+5.0 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Role scores low · most senior buyer: MD & Group CEO (CEO, chair and 10% owners score lowest)

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Behrenbruch ChristianMD & Group CEO
●●
Smith Darren CharltonGroup Chief Financial Officer
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION98%Largest buyer: Behrenbruch Christian · $996.7K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-04-28–2026-04-29

Roles in the peak window: MD & Group CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

59.6 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 60.1
  2. 60.0
  3. 59.9
  4. 59.7
  5. 59.6

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

3Purchases
0Sales
0Other Form 4 lines
2SEC filings · 365 days
BUYING3 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-5.8%
3M
+2.2%
6M
+6.4%
12M
+9.5%

Volatility & liquidity

Volatility
57.0%
Beta
—
Avg daily value
USD 3.0M

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
426,829
Previous report
352,524
Avg daily volume
542,786
Days to cover
≤ 1.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-07Smith Darren CharltonPurchase (P)Ordinary Shares2,071USD 9.66USD 20,006SEC filing ↗
2026-04-29Behrenbruch ChristianPurchase (P)Ordinary Shares33,435USD 14.87USD 497,178SEC filing ↗
2026-04-28Behrenbruch ChristianPurchase (P)Ordinary Shares34,500USD 14.48USD 499,560SEC filing ↗

Form 4 evidence

3 transaction lines in the latest 365-day window; 3 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-07Smith Darren CharltonPurchase (P)Ordinary Shares2,071USD 9.66USD 20,006SEC filing ↗
2026-04-29Behrenbruch ChristianPurchase (P)Ordinary Shares33,435USD 14.87USD 497,178SEC filing ↗
2026-04-28Behrenbruch ChristianPurchase (P)Ordinary Shares34,500USD 14.48USD 499,560SEC filing ↗
Show recent Form 4 evidence (3 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-07Smith Darren CharltonPurchase (P)Ordinary Shares2,071USD 9.66USD 20,006SEC filing ↗
2026-04-29Behrenbruch ChristianPurchase (P)Ordinary Shares33,435USD 14.87USD 497,178SEC filing ↗
2026-04-28Behrenbruch ChristianPurchase (P)Ordinary Shares34,500USD 14.48USD 499,560SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerTLX
CIK0002007191
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq; OTC

Data coverage

Local Form 4 history3 transaction lines from 2026-04-28 to 2026-09-07
3 P purchase lines · 0 S sale lines · 0 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.